Send to

Choose Destination
Indian J Biochem Biophys. 2004 Dec;41(6):273-80.

Role of protein tyrosine kinase inhibitors in cancer therapeutics.

Author information

Govt. College of Pharmacy, Karad, Maharashtra 415 124, India.


Protein tyrosine kinases (PTKs) are critical in regulating cell growth and differentiation and are deeply involved in several cancers. PTK-inhibitors are mainly ATP-site directed and are finding use in the treatment of several cancers, and more than 30 such agents are now in phase I-III clinical trials. The present review focuses mainly on the development of PTK inhibitors in clinical trials, with special emphasis on imatinib mesylate, a rationally designed, potent oral anticancer agent and selective inhibitor for Abl tyrosine kinase, including Bcr-Abl, C-kit and platelet-derived growth factor-receptor tyrosine kinases, which has been implicated in several malignancies, including chronic myeloid leukemia and gastrointestinal stromal tumour.

[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center